|Articles|December 10, 2001
CDER News 12/5 and 12/6 2001
Author(s)BioPharm International Editors
New and generic drug approvals
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Clears In-Vivo Gene Editing Therapy PBGENE-DMD for Duchenne Trial
2
Preclinical Study Finds Subcutaneous Nanotrastuzumab Comparable to Herceptin HYLECTA in Minipig Model
3
The Clinical Execution Gap: Why Great Science Often Fails at the Trial Stage
4
European Commission Approves Uplizna as Add-On Therapy for Antibody-Positive Generalized Myasthenia Gravis
5